Table 1.
First-line therapy initiated from 2001 to 2009
| Treatment type | Number | Percent |
|---|---|---|
| R-mono | 594 | 100 |
| R + IV chemo | ||
| R + CHOP | 46 | 6.6 |
| R + CVP | 76 | 10.9 |
| R + FC | 192 | 27.6 |
| R + F | 303 | 43.5 |
| R + C | 62 | 8.9 |
| R + other | 17 | 2.4 |
| Total | 696 | 100 |
| IV chemo-only | ||
| CHOP | 82a | 5.3 |
| CVP | ||
| FC | 63 | 4.1 |
| F | 423 | 27.4 |
| C | 22 | 1.4 |
| Other chemo | 345 | 22.3 |
| Unknown chemo | 609 | 39.4 |
| Total | 1,544 | 100 |
R-mono rituximab monotherapy; R + IV chemo rituximab plus intravenous chemotherapy; IV chemo-only intravenous chemotherapy only; CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP cyclophosphamide, vincristine, and prednisone; FC fludarabine and cyclophosphamide
aCells with counts of less than 11 are combined in compliance with the National Cancer Institute data use agreement for small cell sizes